Compositions and Methods for Treatment of Eye Disorders
AssigneeSarcode Bioscience Inc.
InventorsThomas Gadek, John Burnier, Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Claims39
A method of treating dry eye disease in a subject in need thereof comprising administering to said subject an effective amount of a lymphocyte function associated antigen-1 (LFA-1) antagonist or a pharmaceutically acceptable salt or ester thereof, wherein the LFA-1 antagonist is a peptide, a small organic molecule, or a combination thereof.
21-30. (canceled)
An ocular pharmaceutical formulation comprising an LFA-1 antagonist, a pharmaceutically acceptable carrier, and a pharmaceutically acceptable excipient.
36-44. (canceled)
48-49. (canceled)
52-53. (canceled)
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.